Who is sponsoring NCT04183569?

NCT04183569 is sponsored by University Hospital, Bordeaux.

What drugs are being tested in NCT04183569?

Interventions in NCT04183569: Sequencing RNA..

What condition does NCT04183569 study?

NCT04183569 studies Lymphoma, Large B-Cell, Diffuse.

Is NCT04183569 still recruiting?

NCT04183569 is currently status unknown. Last updated 29 April 2020.

Last reviewed 2020-04-29 · How we verify

NCT04183569: PROTEOM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma

Status unknown Last updated 29 April 2020

What this trial tests

trial testing Sequencing RNA. in Lymphoma, Large B-Cell, Diffuse in 32 participants. Status unknown.

Timeline

19 February 2019

Primary endpoint
1 May 2020

1 May 2020

Quick facts

Lead sponsor	University Hospital, Bordeaux
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	32
Start date	19 February 2019
Primary completion	1 May 2020
Estimated completion	1 May 2020
Sites	1 location across France

Drugs / interventions tested

Sequencing RNA.

Conditions studied

Lymphoma, Large B-Cell, Diffuse — all drugs for Lymphoma, Large B-Cell, Diffuse →

Sponsor

University Hospital, Bordeaux

Who can join

18 and older, any sex, with Lymphoma, Large B-Cell, Diffuse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is performed on a single-center retrospective cohort of 32 patients LBC-TJ treated with R-chemotherapy for which data collection was carried out in homogeneous and prospectively followed according to international standards through RCP monthly cutaneous lymphomas managed by Professor Beylot-Barry and inclusion of cases in the national database of rare cancer network French Study Group of Cutaneous Lymphomas in Bordeaux managed by Prof. Beatrice Vergier. Fourteen patients responded to the R-PCT against 18 non-responders, 14 patients for whom we have the sample to recidivism.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lymphoma, Large B-Cell, Diffuse

Currently open trials in the same condition.

NCT06890884 — A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R- · Phase 2 · recruiting
NCT06254495 — A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers · Phase 1 · active not recruiting
NCT06093841 — Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL · Phase 2 · active not recruiting
NCT05800366 — A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma · Phase 2 · recruiting
NCT05798156 — Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell · Phase 2 · active not recruiting

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04183569 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
Last refreshed: 29 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04183569.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing